Novavax Inc (NVAX NASDAQ) stock market data APIs
$7.4591
-0.05(-0.7%)
as of November 7, 2025
Try our APIs with
free plan!
Novavax Inc Financial Data Overview
Price chart is built with
Anychart
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Prev. Close
7.4591
Open
7.4086
High
7.5773
Low
7.3047
52 wk Range
5.01-11.55
Market Cap
1 208 M
P/E Ratio
3.7015
Shares Outstanding
162 M
Revenue
1 065 M
EPS
-1.25
Beta
2.295
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novavax Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novavax Inc data using free add-ons & libraries
Get Novavax Inc Fundamental Data
Novavax Inc Fundamental data includes:
- Net Revenue: 1 065 M
- EBITDA: 457 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.4919
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novavax Inc News
New
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
Novavax NVAX incurred a loss of 62 cents per share in the third quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.08 per share. In the year-ago quarter, the company...
Novavax Inc (NVAX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
This article first appeared on GuruFocus. Release Date: November 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Novav...
Novavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition
Earnings Call Insights: Novavax (NVAX) Q3 2025 MANAGEMENT VIEW * John Jacobs, President, CEO & Director, stated that Novavax has made significant progress in Q3 by strengthening existing partnersh...
NVAX December 26th Options Begin Trading
Investors in Novavax, Inc. (Symbol: NVAX) saw new options begin trading today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX opti...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
